Drug combination before bladder cancer surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests two drugs, trastuzumab rezetecan and adebrelimab, given before surgery for a type of bladder cancer that has grown into the muscle. The goal is to see if this combination can shrink the tumor and improve outcomes for patients whose cancer cells have a certain protein called HER2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with muscle-invasive bladder cancer that has not spread to other organs.
- Your tumor has a protein called HER2 (a score of 2+ or 3+ on a test).
- You have not had chemotherapy before for this cancer.
- You are generally in good health, with adequate organ function.
- You are willing to use effective contraception if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two drugs before and after surgery can help people with HER2-positive bladder cancer that has grown into the bladder muscle. The goal is to see if this approach can shrink or control the cancer before the bladder is removed.
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This trial tests a combination of two drugs—vedisertib (RC48) and toripalimab—for people with bladder cancer that has invaded the muscle but hasn't spread. The goal is to preserve the bladder while treating the cancer.
This trial tests a new combination of two drugs before bladder removal surgery for patients with HER2-positive muscle-invasive bladder cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Muscle-Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.